Sunshine Biopharma (SBFM) Non-Current Assets (2015 - 2026)

Sunshine Biopharma has reported Non-Current Assets for 12 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 33.13% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 33.13% YoY), and the FY2025 full-year result was $3.2 million, down 29.79% from the prior year.
• Non-Current Assets for Q1 2026 stood at $3.1 million, down from $3.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $4.7 million in Q1 2025, with the low at $1642.0 in Q2 2022.
• Historically, Non-Current Assets has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets sank 87.82% — and 2023, when it jumped 140662.06%.
• Sunshine Biopharma's Non-Current Assets stood at $1.9 million in 2022, then advanced by 27.2% to $2.5 million in 2023, then jumped by 86.98% to $4.6 million in 2024, then retreated by 29.79% to $3.2 million in 2025, then slipped by 2.43% to $3.1 million in 2026.
• The last three Non-Current Assets figures came in at $3.1 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.